Investing.com - Protagonist Therapeutics (NASDAQ: PTGX) reported fourth quarter EPS of $0.44, $0.58 better than the analyst estimate of $-0.14. Revenue for the quarter came in at $60M versus the consensus estimate of $40M.
Protagonist Therapeutics's stock price closed at $29.59. It is up 59.43% in the last 3 months and up 89.07% in the last 12 months.
Protagonist Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Protagonist Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Protagonist Therapeutics's Financial Health score is "good performance".
Check out Protagonist Therapeutics's recent earnings performance, and Protagonist Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar